Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 12/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 12/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 10/20 | 0.44 |
| ▸ | CCR5 | P51681 | 6/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3022067 | 1.00 | CHRM4 (0.44) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3020708 | 0.92 | CHRM4 (0.43) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3020712 | 0.92 | CHRM4 (0.43) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3017060 | 0.85 | CHRM4 (0.45) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3017056 | 0.85 | CHRM4 (0.45) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3020775 | 0.85 | CHRM4 (0.56) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3020772 | 0.85 | CHRM4 (0.56) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3022959 | 0.84 | CHRM4 (0.45) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3022961 | 0.84 | CHRM4 (0.45) | CHRM4CHRM5CHRM1CHRM3CHRM2 | |
| SCHEMBL3019620 | 0.81 | CHRM4 (0.52) | CHRM4CHRM5CHRM1CHRM3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| US-8426443-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2013-04-23 | — | — | US | disclosed |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | GLAXO GROUP LIMITED (GB) | 2012-12-13 | — | — | US | disclosed |
| US-8278328-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-8278328-B2 | Compounds which have activity at M1 receptor and their uses in medicine | GLAXO GROUP LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | Glaxo Group Limited a corporation | 2010-08-12 | — | — | US | disclosed |
| EP-2194982-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | Glaxo Group Limited (GB) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009037294-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009037294-A1 | COMPOUNDS WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204272-A1 | Compounds which have activity at M1 receptor and their uses in medicine | CHRM1, CHRM2, CHRM5 | CHRM4 4/4885CHRM5 3/4885CHRM1 1/4885 |
| US-20120316196-A1 | Compounds Which Have Activity at M1 Receptor and Their Uses in Medicine | CHRM1, CHRM2, CHRM5 | CHRM4 4/4885CHRM5 3/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.